A new OHE Research Paper assesses the nature of evidence used to reach HTA decisions which NICE have classified as “Recommended in Line with Clinical Practice” between 2007 and mid-2016. The level of patient access associated with these decisions has also been assessed.
OHE has published a new report discussing a framework to help middle-income countries efficiently identify medicines for formulary inclusion. A second publication applies this framework to the Mexican decision making system as a case study.
This paper uses MCDA to obtain preferences on decision criteria across three stakeholder groups (patients, clinicians and payers) in Italy and then uses these preferences to assess the value of obinutuzumab for rituximab-refractory iNHL.
A new OHE Research Paper has just been published on the topic of uncertainty and risk in health technology assessment (HTA) decision making. The report is concerned with uncertainty as it affects the cost effectiveness aspects of HTA.
ISPOR’s 19th Annual European Congress was held in Vienna, 29 October – 2 November 2016. Several members of the OHE team attended and contributed to the conference. This post contains a summary of their activity.
A new study which explores the relationship between sub-Saharan African authors and their respective co-authors has been published in Globalization and Health. The study was a collaboration between OHE, NICE International and PRICELESS.